About
Beta Bionics is a company that specializes in the development of medical devices for the treatment of diabetes. Founded in 2015, Beta Bionics is focused on creating innovative solutions to improve the lives of individuals living with diabetes, particularly those with type 1 diabetes.
One of the most notable products developed by Beta Bionics is the “iLet.” The iLet is an advanced automated insulin delivery system designed to help people with diabetes manage their blood glucose levels more effectively. It is essentially an artificial pancreas that combines insulin delivery and glucose monitoring in a closed-loop system.
The device continuously monitors the user’s blood sugar levels and delivers the appropriate amount of insulin to maintain target blood glucose levels without the need for constant manual intervention. This can help reduce the risk of hypoglycemia (low blood sugar) and hyperglycemia (high blood sugar) episodes, which are common challenges for people with diabetes.
The iLet comes in two versions: the insulin-only iLet and the bihormonal iLet. The bihormonal version not only delivers insulin but also glucagon, a hormone that raises blood sugar levels when needed. This dual-hormone approach offers even more precise control over blood glucose levels, providing an additional layer of safety and flexibility for individuals with diabetes.
Beta Bionics has conducted clinical trials and studies to demonstrate the effectiveness and safety of its iLet system. These trials have shown promising results, with many participants experiencing improved blood sugar control and reduced episodes of hypoglycemia.
Beta Bionics Medical Devices
1 – iLet Bionic Pancreas:
The flagship product of Beta Bionics is the iLet Bionic Pancreas, an automated insulin delivery system designed for individuals with type 1 diabetes. The iLet operates as a closed-loop system, seamlessly integrating continuous glucose monitoring (CGM) with the highly regarded Dexcom G6, thereby automating insulin delivery.
It continuously monitors the user’s blood sugar levels and calculates the precise amount of insulin needed to keep glucose levels within a target range. This reduces the need for constant manual adjustments and bolus insulin injections, leading to better glucose control and a reduced risk of hypoglycemia.
